Names | |
---|---|
IUPAC name
2-Morpholin-4-yl-8-phenylchromen-4-one
|
|
Other names
2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
|
|
Identifiers | |
154447-36-6 | |
3D model (Jmol) | Interactive image |
ChEMBL | ChEMBL98350 |
ChemSpider | 3835 |
6004 | |
PubChem | 3973 |
|
|
|
|
Properties | |
C19H17NO3 | |
Molar mass | 307.35 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
what is ?) | (|
Infobox references | |
LY294002 is a morpholine-containing chemical compound that is a potent inhibitor of numerous proteins, and a strong inhibitor of phosphoinositide 3-kinases (PI3Ks). It is generally considered a non-selective research tool, and should not be used for experiments aiming to target PI3K uniquely.
Two of these are the proto-oncogene serine/threonine-protein kinase (PIM1) and the phosphatidylinositol-4,5-bisphosphate 3-kinase P110 gamma|catalytic subunit gamma isoform. With an IC50 of 1.4 µM it is somewhat less potent than wortmannin, another well-known PI3 kinase inhibitor. However, LY294002 is a reversible inhibitor of PI3K whereas wortmannin acts irreversibly.
Application of LY294002 causes a substantial acceleration of MEPP frequency (150 μM) at the frog neuromuscular junction through a mechanism that is independent of intraterminal calcium. LY294002 causes the release of MEPPs through a perturbation of synaptotagmin function.
LY294002 is also a BET inhibitor (eg of BRD2, BRD3, and BRD4).
It has been shown that LY294002 administration has an additive effect on quercetin antiviral activity against hepatitis C virus.